摘要
目的探讨左卡尼汀联合福辛普利对糖尿病肾病(diabetic nephropathy,DN)患者的疗效。方法选取近1年收治的60例DN患者,将其随机分为研究组和对照组,每组患者30例,对照组患者采取常规治疗+福辛普利治疗,研究组患者在此基础上,联合左卡尼汀治疗,两组患者均连续治疗6个月,对比两组患者的疗效及对血糖水平、肾功能、血清胱抑素C(CysC)、血视黄醇结合蛋白(RBP)、高敏C反应蛋白(hs-CRP)的影响。结果两组患者经过6个月的治疗后,研究组患者的治疗有效率为90.0%,明显高于对照组患者66.7%(P<0.05);两组患者治疗前后糖化血红蛋白(HbA1c)、餐后血糖(FPG)、餐后2 h血糖(2 h PG)对比差异无统计学意义(P>0.05);两组患者治疗前血肌酐(SCr)、尿素(BUN)、24 h尿白蛋白排泄率(UAER)对比差异无统计学意义(P>0.05),经过6个月治疗,研究组患者各项肾功能指标均明显低于对照组(P<0.05);两组患者治疗前CysC、RBP、hs-CRP对比差异无统计学意义(P>0.05),经过6个月治疗,研究组患者明显低于对照组(P<0.05)。结论左卡尼汀联合福辛普利治疗DN,可降低血清CysC、RBP、hs-CRP,可有效改善患者的临床症状,预防病情向肾衰竭发展。
Objective To investigate the therapeutic effect of levocarnitine combined with fosinopril on diabetic nephropathy(DN).Methods 60 cases treated by almost 1 year in our DN patients,randomly divided into research group and the control group,each group of 30 cases of patients,patients with the control group treated with conventional treatment+fosinopril,the patients in the study group were given levocarnitine,two groups were treatment for 6 months,and the curative effect,the urinary inhibition on blood sugar level,renal function,serum C(CysC),blood retinol binding protein(RBP),high-sensitivity c-reactive protein(hs-CRP)in two groups were compared.Results After treatment for 6 months,the effective rate was 90.0%in the study group and 66.7%in the control group.The effective rate in the study group was significantly higher than that in the control group(P<0.05).There were no statistically significant differences in HbA1c,postprandial blood glucose(FPG)and 2 h postprandial blood glucose(2 h PG)between the two groups before and after treatment(P>0.05).The blood creatinine(SCr),blood urea(BUN),urinary albumin excretion rate(UAER)24 h before the treatment of the two groups of patients had no statistical difference(P>0.05).After treatment for 6 months,the study group with various renal indicators are significantly lower than the control group(P<0.05).There was no significant difference in CysC,RBP and hs-crp between the two groups before treatment(P>0.05).After 6 months of treatment,patients in the study group were significantly lower than those in the control group(P<0.05).Conclusion The DN,effect of levocarnitine combined with fosinopril in the treatment could reduce the serum CysC、RBP、hs-CRP,effectively improving the clinical symptoms of patients,effectively preventing the development of the disease to renal failure,and has important clinical application value.
作者
赵宇
ZHAO Yu(Department of Nephrology,Tianjin Xiqing Hospital,Tianjin 300380,China)
出处
《中国处方药》
2021年第9期123-125,共3页
Journal of China Prescription Drug
关键词
左卡尼汀
福辛普利
糖尿病肾病
疗效
Levocarnitine
Fosinopril
Diabetic nephropathy
The curative effect